v3.26.1
Subsequent Events (Details Narrative) - USD ($)
 3 Months Ended
Jul. 30, 2026
Jul. 28, 2026
Jul. 23, 2026
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Common Stock [Member]              
Subsequent Event [Line Items]              
Stock issued during period shares new issues       50,330 86,956 1,395,760 62,267
Subsequent Event [Member]              
Subsequent Event [Line Items]              
Gross proceeds from issuance of private placement $ 200,000,000            
Litigation settlement expense     $ 650,000        
Description for termination of license Agreement     In addition, we agreed to grant to Elion a non-voting equity interest equal to seven and one-half percent (7.5%) of the fully diluted pre-money equity capitalization of any newly formed entity whose assets include one or more of PCS499, PCS12852, and/or PCS11T, if the formation or spin-out is completed within three hundred sixty-five (365) days following the effective date of the Settlement Agreement. On August 7, 2026, the filed stipulation became effective as a final dismissal with prejudice.        
Subsequent Event [Member] | Series A Preferred Stock [Member]              
Subsequent Event [Line Items]              
Conversion of shares   1,000          
Subsequent Event [Member] | Securities Purchase Agreement [Member]              
Subsequent Event [Line Items]              
Gross proceeds from issuance of private placement $ 200,000,000            
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Series A Preferred Stock [Member]              
Subsequent Event [Line Items]              
Common shares issuable upon conversion of preferred stock 163,774,679            
Stock issued during period shares new issues 163,774.679            
Share issued price per shares $ 1,221.19            
Conversion price per share $ 1.22119            
Subsequent Event [Member] | Vidya Therapeutics, Inc. [Member] | Series A Preferred Stock [Member]              
Subsequent Event [Line Items]              
Shares issued on consideration   142,744.100          
Conversion of shares   1,000          
Description for equity interest   As a result of the acquisition and private placement transactions, our equity holders immediately prior to the Vidya Acquisition owned approximately 1.0% of our common stock, equity holders of Vidya immediately prior to the Vidya Acquisition owned approximately 46.0% of our common stock and investors in the 2026 Private Placement owned approximately 53.0% of our common stock, in each case, calculated on a fully-diluted basis (without giving effect to any beneficial ownership limitations and assuming the conversion in full of the Series A Preferred Stock) and based on our and Vidya’s implied equity values.          
Subsequent Event [Member] | Vidya Therapeutics, Inc. [Member] | Merger Agreement [Member] | Series A Preferred Stock [Member]              
Subsequent Event [Line Items]              
Common shares issuable upon conversion of preferred stock   142,744,100          
Subsequent Event [Member] | Vidya Therapeutics, Inc. [Member] | Common Stock [Member] | Merger Agreement [Member]              
Subsequent Event [Line Items]              
Shares issued on consideration   558,398